From the Journals
Clinical Guidelines

Optimizing the Care of Patients With Higher-Risk Myelofibrosis

Share

Myelofibrosis (MF) is a rare myeloproliferative neoplasm characterized by disruptions in the JAK-STAT signaling pathway and significant clinical manifestations such as splenomegaly and fatigue. The latest diagnostic criteria, established by the ICC and WHO in 2022, highlight risk stratification methods like MIPSS-70 for prognoses. Treatment options include the only potential cure, allogeneic stem cell transplantation, and several FDA-approved JAK inhibitors to manage symptoms and side effects. Notably, care needs to be taken with potential adverse effects including cytopenias and infections.

Original Source(s)

Optimizing the Care of Patients With Higher-Risk Myelofibrosis

  • by JADPRO Staff

  • March 26, 2025

  • 6 min

Related Content

Enhancing Immune Thrombocytopenia Education and Support: Insights From a Learning Exchange Program

Navigating Complex Cases With Empathetic Communication

Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Monocytosis

The second case in our series on myeloid neoplasms